INFQ:NYSEInfleqtion, Inc. Analysis
Data as of 2026-05-21 - not real-time
$11.18
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Infleqtion’s stock is trading at $11.18, which sits below its 20‑day ($12.52), 50‑day ($11.99) and 200‑day ($12.12) simple moving averages, signaling a short‑term downtrend. The bearish MACD (line –0.28 vs signal –0.03) and a neutral RSI of 42 further suggest limited upside momentum, while the price is perched just above the identified support at $10.32 and well under the resistance at $15.88.
Fundamentally, the company posted a 16.6% revenue growth to $32.5 M, but that growth is dwarfed by an operating loss of –107% and a net loss margin of –98%, leaving both cash flow and free cash flow deeply negative. With a price‑to‑sales multiple of 75× and negative earnings (PE –74), the stock appears markedly overvalued, compounded by extreme 30‑day volatility (≈103%) and a beta of 4.93, indicating high market sensitivity. Despite a solid cash buffer of $46 M against $5.15 M of debt, the balance sheet shows a negative book value per share (‑$4.15).
Fundamentally, the company posted a 16.6% revenue growth to $32.5 M, but that growth is dwarfed by an operating loss of –107% and a net loss margin of –98%, leaving both cash flow and free cash flow deeply negative. With a price‑to‑sales multiple of 75× and negative earnings (PE –74), the stock appears markedly overvalued, compounded by extreme 30‑day volatility (≈103%) and a beta of 4.93, indicating high market sensitivity. Despite a solid cash buffer of $46 M against $5.15 M of debt, the balance sheet shows a negative book value per share (‑$4.15).
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below key moving averages
- Bearish MACD histogram
- Proximity to support level
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Revenue growth of 16.6% YoY
- Analyst consensus of strong buy with 87% upside
- Substantial cash reserves relative to debt
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High beta and volatility indicating market risk
- Persistent negative earnings and cash flow
- Potential strategic value in quantum technology market
Key Metrics & Analysis
Financial Health
Revenue Growth16.60%
Profit Margin-97.94%
P/E Ratio-74.2
ROE-41.57%
ROA-21.88%
Debt/Equity5.82
P/B Ratio-2.7
Op. Cash Flow$-24145000
Free Cash Flow$-27087750
Industry P/E38.8
Technical Analysis
TrendNeutral
RSI42.6
Support$10.32
Resistance$15.88
MA 20$12.52
MA 50$11.99
MA 200$12.12
MACDBearish
VolumeStable
Fear & Greed Index90.29
Valuation
Target Price$21.00
Upside/Downside87.84%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta4.93
Volatility102.95%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.